Related Experiment Videos
Rapamycin in lung transplantation: preliminary results
P Ussetti1, R Laporta, A de Pablo
1Lung and Cardiopulmonary Transplant Unit, Clínica Puerta de Hierro, Madrid, Spain. pied2152@separ.es
Transplantation Proceedings
|September 10, 2003
Summary
Rapamycin offers a viable alternative for lung transplant patients experiencing chronic rejection or calcineurin inhibitor (CNI) toxicity. This immunosuppressive drug demonstrated benefits in pulmonary function and CNI-related adverse effects.
Area of Science:
- Immunology
- Transplantation Medicine
- Pharmacology
Background:
- Rapamycin is a potent immunosuppressive drug with a distinct mechanism and adverse effect profile compared to calcineurin inhibitors (CNIs).
- Lung transplant recipients often face challenges with chronic rejection and CNI-induced toxicity.
Purpose of the Study:
- To evaluate the efficacy and safety of rapamycin in lung and heart-lung transplant recipients at a single center.
- To analyze outcomes in patients with chronic rejection and/or CNI toxicity.
Main Methods:
- Retrospective analysis of 7 lung and heart-lung transplant patients treated with rapamycin since October 2001.
- Rapamycin was administered alongside CNIs for chronic rejection or as a replacement for CNIs in cases of toxicity.
- Patient outcomes, including pulmonary function, CNI-related adverse effects, and complications, were assessed.
Main Results:
- Pulmonary function stabilized in 3 of 4 patients with chronic rejection treated with rapamycin.
- Eliminating CNIs in patients with toxicity did not lead to pulmonary deterioration; kidney function and visual acuity improved in relevant cases.
- Two infectious complications (pneumococcal pneumonia, pulmonary aspergillosis) occurred but were successfully treated.
Conclusions:
- Rapamycin serves as an effective alternative immunosuppressive agent for lung transplant recipients.
- It can be beneficial for managing chronic rejection and mitigating CNI-induced toxicity, including renal and visual impairments.